RxDoctor Payments Data

Ryan Ferrell, MD

Cardiovascular Disease · Kansas City, KSNPI 1891805933

Payments from drug & device makers

$2,071in general payments, 2019–2025

Across 88 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$659
  • Amgen$358
  • E.r. Squibb & Sons, L.L.C.$335
  • Pfizer$171
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$89
  • Novo Nordisk$62
  • plus $397 from 13 others

What the payments were for

  • Food & beverage$2,071100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,071 in reported general payments places this provider in the 40th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$153,669
Medicare patients
1,333
Services billed
2,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$177,705
Repatha SureclickEvolocumab176$97,244
XareltoRivaroxaban37$46,760
JardianceEmpagliflozin33$37,410
Praluent PenAlirocumab36$27,176
VascepaIcosapent Ethyl35$20,330
EntrestoSacubitril/Valsartan18$17,477
FarxigaDapagliflozin Propanediol13$15,763
Dofetilide32$5,074
Ezetimibe210$3,869
Atorvastatin Calcium372$3,600
Metoprolol Succinate220$2,047
FenofibrateFenofibrate Nanocrystallized37$2,027
Rosuvastatin Calcium174$1,772
Losartan Potassium201$1,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$171$177,705142 claims
Johnson & JohnsonXarelto$13$46,76037 claims
Boehringer IngelheimJardiance$15$37,41033 claims
NovartisEntresto$29$17,47718 claims
AstraZenecaFarxiga$33$15,76313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →